What is the Impact Factor of Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration?

According to the latest Clarivate Journal Citation Reports (JCR), the Journal Impact Factor of Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration is 2.40, ranking in quartile Q3 of Web of Science (SCIE).

Is Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration indexed in Web of Science or Scopus?

Yes, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration is indexed in Web of Science (SCIE, Q3 quartile). Furthermore, in Scopus (SCImago), it holds an SJR rating of 0.990 (Q1) and an H-index of 93.

Who publishes Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration and what is the Article Processing Charge (APC)?

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration is published by Informa Healthcare. The estimated Article Processing Charge (APC) is approximately $3,327 USD, subject to institutional waivers and corresponding author affiliations.

What is the ISO-4 abbreviation and acronym of Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration?

The official ISO-4 abbreviation of Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration is "AMYOTROPH LAT SCL FR" with common acronym "als". This standardized title abbreviation is used in citation lists conforming to IEEE, APA, Harvard, or Vancouver styles.

WoS SCIE Q3Scopus Q1SCImago #4,976Hybrid

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Acronym:als

•

Abbreviation (ISO):AMYOTROPH LAT SCL FR

•

Identifier (ISSN):2167-8421(Print)/2167-9223(Online)

•

Publisher:Informa Healthcare

Official Website Submission Portal Compare

Clarivate IF (2026)

2.4↓ -0.4

Journal Impact Factor

IF Trend↓

WoS Quartile

WoS SCIEJCR Quartile

Clarivate WoS JCR

WoS Categories↓

JCR Release Date: 2026-06-17

Impact Factor Trend (2018–2026)

Clarivate IF trend for Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

WoS Q3

Annual Impact Factor Metric

Current (2026):2.4

Scopus SJR & RankScopus Q1

0.99

#4,976

SCImago Journal Rank citation prestige weighting

Scopus Year: 2025

H-Index (2025)

93 papers with at least that number of citations each

WoS: SCIE / JCRQ3

Self-Citation Rate12%

Safe Level (< 15%)Warning Level (> 20%)

Self-citation below 15% indicates strong scholarly independence.

Volume & Open AccessHybrid

107articles/year

33.9% Gold OA•85.71% Original Research

Aims & Scope

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration is an exciting new initiative. It represents a timely expansion of the journal Amyotrophic Lateral Sclerosis in response to the clinical, imaging pathological and genetic overlap between ALS and frontotemporal dementia. The expanded journal provides outstanding coverage of research in a wide range of issues related to motor neuron diseases, especially ALS (Lou Gehrig’s disease) and cognitive decline associated with frontotemporal degeneration. The journal also covers related disorders of the neuroaxis when relevant to these core conditions.

Topics Covered (Recognized by AI)

Medicine88.7%Internal medicine81.1%Pathology78.3%Disease71.6%Biology70.3%Amyotrophic lateral sclerosis62.3%Psychology54.1%Psychiatry32.2%Chemistry31.7%Genetics31.6%Neuroscience30.6%Mathematics29.7%Biochemistry29.2%Computer science24.2%Statistics23.2%Surgery20.9%

Primary Research Areas

Clinical Neurology

Official Website NLM PubMed Catalog Submission Portal SCImago Profile

0 calls

Special Issues

Calls for Papers

No active Calls for Papers found for this journal.

Expand

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI

JCRSCIE2026

CLINICAL NEUROLOGY

Rank168/296

IndexSCIE

JCISCIE2026

CLINICAL NEUROLOGY

Rank126/296

IndexSCIE

Category	Index	Rank	Quartile
CLINICAL NEUROLOGY	JCRSCIE	168/296	Q3
CLINICAL NEUROLOGY	JCISCIE	126/296	Q2

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year

2026Latest

IF2.4

Articles / Year72

Total Citations16

2025

IF2.8

Articles / Year135

Total Citations229

2024

IF2.5

Articles / Year120

Total Citations472

2023

IF2.8

Articles / Year102

Total Citations757

2022

IF3.528

Articles / Year87

Total Citations899

Year	Impact Factor	Articles / Year	Total Citations
2026	2.4	72	16
2025	2.8	135	229
2024	2.5	120	472
2023	2.8	102	757
2022	3.528	87	899
2021	4.092	127	1,474
2020	3.286	114	2,299
2019	2.883	123	2,787
2018	2.982	80	1,542
2017	—	134	4,324
2016	—	116	2,649
2015	—	110	3,174

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #4,976Scopus Q1SCImago Profile

Scopus Coverage:2013-2026

•

Scopus Broad Areas:MedicineNeuroscience

Scopus Citation Rank (SJR)Q1

0.99

Weighted prestige citation metric per document indexed in the Scopus database.

Quartile: Scopus Q1

Citations / Doc (2 years)

2.74

Average citations received per document published in the 2-year window.

2-Year Citation Window

Estimated Publication Fee (APC)

$3,327 USD

Estimated Article Processing Charge for Open Access publication.

Estimated cost / article

Scopus 3-Year Publication & Citation Window

3-Year Citations779

3-Year Documents297

Citable Documents288

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)0

Citations in government and international policy documents

Female Author Rate51.6%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

Medicine (miscellaneous)Q1

NeurologyQ2

Neurology (clinical)Q2

Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth

Self-citation: 12%

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):

3区 (Zone 3)Medicine

Minor Category (Specific Field):

3区CLINICAL NEUROLOGY

CAS Early Warning List History:

Updated annually: 2020 – 2024

2020

Not warned

2021

Not warned

2022

Not warned

2023

Not warned

2024

Not warned

Academic Intelligence Overview & Context

ImpaQ Analysis

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration (acronym: als, abbr: AMYOTROPH LAT SCL FR, ISSN: 2167-8421) is a peer-reviewed international scholarly journal in the field of CLINICAL NEUROLOGY, published by Informa Healthcare in England. The periodical holds a Journal Impact Factor (JIF) of 2.40, ranking in quartile Q3 of Web of Science (SCIE), a Scopus SJR indicator of 0.990 (Q1), an H-index of 93.

The journal enforces rigorous peer evaluation with an annual output of approximately 107 scientific articles. In terms of accessibility and author fees, it operates under the Hybrid model with an estimated APC of $3,327 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.